Skip to main content
. 2023 Dec 31;14(1):e12327. doi: 10.1002/clt2.12327

TABLE 2.

Comparison of demographic and laboratory data between cases of ABPA and ABPM‐Sc either positive or negative for Aspergillus‐specific IgE.

A. fumigatus‐specific IgE ABPM‐Sc ABPA p*
Negative n = 10 Positive n = 19 n = 46
Age at onset of ABPM, y 65 (44–77) 57 (38–66) 67 (51–71) 0.11
Women 7 (70) 12 (63) 27 (59) 0.84
Asthma* 3 (30) 11 (58) 32 (70) 0.07
Treatment step (1–2/3–5, n [%]) 3/0 (100/0) 6/4 (60/40) 8/22 (27/73) 0.01
Laboratory data at diagnosis
Peripheral blood eosinophil counts (/μL) 523 (263–750) 686 (500–1409) 983 (472–1505) 0.12
Serum IgE levels* (IU/mL) 562*** (194–1571) 2366 (1363–6504) 1954 (530–4583) 0.03
A. fumigatus‐specific IgE*, UA/mL 0.09**,*** (0.05–0.16) 3.13 (0.85–5.66) 11.20 (3.29–30.05) <0.001
A. fumigatus‐specific precipitin/IgG‐positive, n (%) 1** a (17) 6** b (38) 40 (87) <0.001
S. commune‐specific IgE‐positive, n (%) 5 a (83) 6 a (100) NA
S. commune‐specific precipitin/IgG‐positive, n (%) 6 c (86) 5 a (83) NA
Thoracic computed tomography
Central bronchiectasis, n (%) 9 (90) 16 (84) 28 (61) 0.08
Mucus plugs, n (%) 10 (100) 17 (90) 40 (87) 0.76
High attenuation mucus, n (%) 7 (78) 14 (74) 27 (59) 0.43
Infiltration/GGO, n (%) 7 (70) 16 (84) 43 (94) 0.08
Fibrotic/cystic change, n (%) 0 (0) 0 (0) 8 (17) 0.08
FEV1, %predicted* 103 (83–112) 93 (74–107) 80 (65–92) 0.02

Note: Values are medians (interquartile range) or the proportion of patients in each study group, if not otherwise specified.

Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; ABPM‐Sc, ABPM caused by S. commune; FEV1, forced expiratory volume in 1 s; GGO, ground‐glass opacity; Ig, immunoglobulin.

a

n = 6.

b

n = 16.

c

n = 7.

*Among the three groups, **p < 0.05, versus ABPA, ***p < 0.05 versus ABPM‐Sc with sensitization to A. fumigatus.